119,228 Shares in Catalent, Inc. (NYSE:CTLT) Bought by Quantbot Technologies LP

Quantbot Technologies LP purchased a new stake in shares of Catalent, Inc. (NYSE:CTLT) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 119,228 shares of the company’s stock, valued at approximately $7,222,000. Quantbot Technologies LP owned 0.07% of Catalent at the end of the most recent reporting period.

Several other hedge funds and other institutional investors also recently made changes to their positions in the business. Sumitomo Mitsui Trust Group Inc. lifted its position in shares of Catalent by 3.7% during the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 405,318 shares of the company’s stock worth $24,550,000 after purchasing an additional 14,373 shares during the last quarter. Quest Partners LLC lifted its holdings in shares of Catalent by 289.8% during the third quarter. Quest Partners LLC now owns 49,300 shares of the company’s stock worth $2,986,000 after buying an additional 36,652 shares during the last quarter. Swedbank AB bought a new stake in shares of Catalent in the first quarter valued at approximately $1,659,000. New York Life Investment Management LLC grew its stake in shares of Catalent by 67.9% in the second quarter. New York Life Investment Management LLC now owns 297,903 shares of the company’s stock worth $16,751,000 after acquiring an additional 120,502 shares during the last quarter. Finally, Van ECK Associates Corp increased its position in Catalent by 47.4% during the third quarter. Van ECK Associates Corp now owns 124,424 shares of the company’s stock worth $7,391,000 after acquiring an additional 39,983 shares during the period.

Analysts Set New Price Targets

A number of analysts have weighed in on the stock. Baird R W downgraded shares of Catalent from a “strong-buy” rating to a “hold” rating in a report on Tuesday, September 24th. Robert W. Baird reiterated a “neutral” rating and issued a $63.50 target price on shares of Catalent in a research note on Tuesday, September 24th. StockNews.com lowered Catalent from a “hold” rating to a “sell” rating in a research note on Friday. Finally, William Blair reiterated a “market perform” rating on shares of Catalent in a research report on Tuesday, September 3rd. One research analyst has rated the stock with a sell rating and seven have given a hold rating to the company’s stock. According to MarketBeat, Catalent currently has a consensus rating of “Hold” and an average price target of $63.40.

Catalent Stock Up 0.4 %

Shares of CTLT opened at $61.24 on Tuesday. The company has a quick ratio of 1.96, a current ratio of 2.51 and a debt-to-equity ratio of 1.38. The company has a 50-day moving average price of $59.83 and a two-hundred day moving average price of $58.36. The stock has a market cap of $11.12 billion, a price-to-earnings ratio of -27.10, a P/E/G ratio of 2.42 and a beta of 1.16. Catalent, Inc. has a 12 month low of $36.74 and a 12 month high of $61.50.

Catalent (NYSE:CTLT) last announced its quarterly earnings results on Tuesday, November 5th. The company reported ($0.13) EPS for the quarter, missing the consensus estimate of $0.05 by ($0.18). Catalent had a negative net margin of 9.28% and a negative return on equity of 0.66%. The company had revenue of $1.02 billion during the quarter, compared to analyst estimates of $1.06 billion. During the same period in the prior year, the firm earned ($0.10) EPS. Catalent’s quarterly revenue was up 4.2% compared to the same quarter last year. Equities analysts predict that Catalent, Inc. will post 0.84 EPS for the current fiscal year.

Insider Activity

In other news, insider David Mcerlane sold 1,994 shares of the business’s stock in a transaction that occurred on Thursday, September 26th. The stock was sold at an average price of $59.97, for a total value of $119,580.18. Following the transaction, the insider now directly owns 36,304 shares of the company’s stock, valued at $2,177,150.88. The trade was a 5.21 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Michelle R. Ryan sold 2,800 shares of the stock in a transaction that occurred on Monday, November 11th. The stock was sold at an average price of $59.70, for a total value of $167,160.00. Following the sale, the director now owns 10,835 shares in the company, valued at approximately $646,849.50. This trade represents a 20.54 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 5,114 shares of company stock worth $305,931. Corporate insiders own 0.31% of the company’s stock.

Catalent Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.